Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioHarvest Sciences ( (BHST) ) just unveiled an announcement.
BioHarvest Sciences reported a 41% year-over-year increase in revenue for the second quarter of 2025, reaching $8.5 million. This growth was driven by the core VINIA capsule business and new product launches. The company also secured a new CDMO contract and announced the launch of VINIA® Daily Chews 2X Formula. Looking ahead, BioHarvest plans to introduce three growth initiatives, including a professional affiliate program, an electrolyte drink entry, and an AI-enabled CDMO discovery phase, all aimed at expanding market reach and driving revenue growth.
The most recent analyst rating on (BHST) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
BioHarvest Sciences’ overall score is driven by strong earnings call performance and positive technical indicators. However, financial instability and valuation concerns weigh heavily, reflecting significant risks despite growth potential.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a company pioneering its patented Botanical Synthesis technology platform, focusing on the production of high-value plant-based compounds. The company is involved in the health and wellness industry, with a primary focus on products that enhance blood flow and oxygen delivery, such as their VINIA® line of products.
Average Trading Volume: 10,736
Technical Sentiment Signal: Buy
Current Market Cap: $151.8M
See more data about BHST stock on TipRanks’ Stock Analysis page.